The CNS-3D Induced Alzheimer’s Model is a brain organoid assay enabling researchers to evaluate whether therapeutic candidates can reduce or prevent disease progression in patients.

The only assay-ready immunocompetent 3D brain organoid model incorporating microglia for studies of neuroinflammatory mechanisms and drug efficacy

CNS-3D Myelinated Organoids are designed to quantify drug-induced demyelination, observe natural remyelination, and evaluate therapeutic strategies for myelin repair, capturing both injury and recovery within the same biological context.

When asked about the biggest obstacles preventing organoids from reaching their full potential, Alif Saleh, CEO of 28bio, emphasizes that adoption, not technology, is the primary hurdle, particularly in drug discovery, where a staggering 95% failure rate is accepted as the norm.

28bio reports Endurance Study results showing brain organoids predict clinical seizure liability with 83% sensitivity and 89% specificity.

What they mean for medicine and perhaps the future of AI data centers.

28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function.

The idea that a mouse brain or a rat brain or any other animal brain can predict how a human brain would react to a particular drug—it's not credible. Yet up until this point, this has been the only solution that pharma has had available to them.

AxoSim has appointed Stuart Gibb as VP of Sales and Marketing. With over 20 years of experience, Stuart will help accelerate AxoSim's commercial growth in drug discovery and development.

A brain-on-a-chip developer says better preclinical modeling could help move the needle.

AxoSim names Alif Saleh as CEO to advance commercialization. Former CEO Dr. Lowry Curley becomes Chief Scientific Officer to drive scientific innovation.

Serial entrepreneurs Dale Pfost and David Weiner bring broad expertise as AxoSim expands its leadership in human organoid technologies designed to make neurological R&D faster, more efficient and more successful.

Combines three leading live biomimetic organoid platforms designed to make R&D for neurological diseases faster, more efficient and more successful. AxoSim gains expert scientific team and advanced R&D and manufacturing capabilities "upriver" in Minnesota to augment Its "downriver" facilities in New Orleans.

As Vyant Bio continues its wind-down, the neuroscience research assets of its subsidiary StemoniX have officially been picked up by AxoSim, a New Orleans-based drug discovery biotech.

AxoSim has entered a definitive agreement to acquire Vyant Bio's StemoniX microBrain™ platform, uniting top-tier organoid technologies to accelerate neurological drug discovery.